FDA Approved: RIVFLOZA — Original Application (Novo Nordisk)

View source ↗

Summary

The FDA approved Rivfloza (nedosiran) from Novo Nordisk through an Original Application (NDA215842) for the treatment of primary hyperoxaluria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria

Drugs mentioned

• RIVFLOZA (NEDOSIRAN)

Snippet

ORIG AP for RIVFLOZA (NEDOSIRAN)